Purcision™ Inhaled Drug Development Platform

Respiratory drugs have unique challenges that we have consistently solved with Purcision.

Download our summary overview of respiratory opportunities with our Purcision platform here.

Download our extended overview of respiratory opportunities and case studies with our Purcision platform here.

Inhalation Formulation Development Services

Are you developing a respiratory drug and experiencing challenges when it comes to delivery and effectiveness? CritiTech Particle Engineering Solutions has the technology and expertise to be your inhalation CDMO partner. With advanced technology that engineers particles specifically for optimal inhalation formulation development, we can help you overcome your inhaled drug delivery obstacles and achieve the results you want. Our unique  technology results in respiratory pharmaceuticals that are more effective, safer for patients to use and more efficient.

With our patented Purcision™ technology at the heart of our pulmonary drug development services, we can provide the missing piece of the puzzle for you. Whether you are developing a new drug or have an existing pharmaceutical that could use a second chance at success, you can trust our expertise and industry-leading capabilities to guide it to the best possible outcome. To learn more about how we can enhance your inhalation formulation development, reach out to us today.

Inhaled drug delivery has become a growing focal point for our team at CritiTech. It is well established that a strong correlation exists between drug particle size and its ability to remain in the lungs. If the particles are too large (~20µm), they are more likely swallowed than inhaled. If they are too small (<1µm), they will mostly be exhaled. An ideal particle size of 1-10µm can reach the alveolar sacs and be retained to provide continued effect. The key to the most successful inhalation product development is finding the ideal balance between particle size and their surface area. The higher the surface area, the greater bioavailability at the site of the disease.

Our patented Purcision™ supercritical precipitation (SCP) platform, guided by our expert team, has repeatedly demonstrated the ability to engineer particles for successful inhaled drug delivery. Purcision™ allows us to:

  • Enhance bioavailability of poorly soluble drugs
  • Enable improved pharmacokinetics
  • Produce low bulk-density, high surface area particles with aerodynamic properties for nasal and lung delivery that result in higher concentration and extended residency time
  • Provide more efficient dosing – pure drug with no excipients required
  • Design particles that are larger and easier to manipulate to achieve surface area and drug release characteristics for much smaller submicron particles (without the need for added excipients)

Numerous opportunities may exist to use Purcision to reformulate existing drugs into more effective inhaled formulations, including:

  • Broad-spectrum antivirals
  • Broad-spectrum antibiotics
  • Treatment of lung damage
  • Pulmonary protectants
  • Pulmonary therapeutics (pre- and post-exposure) for emerging infectious diseases

Potential Benefits Of Purcision Inhaled Drug Development

  • Higher drug concentration and longer duration of action in the lungs
  • Improved safety – lower and adjustable systemic exposure
  • More efficient dosing – lower dose can achieve effective concentration of drug in the lung
  • Purcision inhaled drugs are pure drug – no excipients, surfactants or coatings required  
  • More doses manufactured with less drug material
  • Ability to fine-tune particle production process to adjust dissolution rate of drugs in the lungs
  • Fast and easy administration using a dry powder inhaler
  • Improved shelf-life, temperature tolerance and transportability versus IV formulations
  • Commercial-scale production

Why Work With CritiTech?

There are a number of reasons why we are your best choice for an inhaled drug development partner. Beyond the Purcision™ platform’s ability to engineer dry powder inhalation formulations that are highly effective, we also have the in-house expertise to accelerate timelines for your respiratory product development and inhalation manufacturing processes. Our drug development leadership team brings more than 150 years of combined experience in the pharmaceutical industry, with more than 100 patents under their belts. If you’re ready to learn more about how we can take your inhalation formulation development to the next level, contact us today.